Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV6 | Q9H1D0 | 14/20 | 0.74 |
| ▸ | SLC18A3 | Q16572 | 2/20 | 0.57 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.57 |
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7303947 | 0.95 | TRPV6 (0.68) | TRPV6SLC18A3MEN1KMT2AKDM4E | |
| SCHEMBL16226898 | 0.90 | TRPV6 (0.82) | TRPV6MEN1KMT2A | |
| Ammonia Solution, Strong SCHEMBL5767783 | 0.89 | TRPV6 (0.80) | TRPV6MEN1KMT2A | |
| SCHEMBL16225912 | 0.86 | TSHR (0.62) | SIGMAR1 | |
| SCHEMBL16225775 | 0.86 | TSHR (0.62) | SIGMAR1 | |
| SCHEMBL16226421 | 0.86 | TRPV6 (0.64) | TRPV6ALDH1A1 | |
| SCHEMBL7329656 | 0.86 | MEN1 (0.74) | SLC18A3SIGMAR1MEN1KMT2A | |
| SCHEMBL8829519 | 0.82 | TRPV6 (0.53) | TRPV6SIGMAR1MEN1KMT2AKDM4E | |
| SCHEMBL16226241 | 0.81 | TRPV6 (0.61) | TRPV6MEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL4797625 | 0.81 | SIGMAR1 (0.69) | TRPV6SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140335050-A1 | METHODS, COMPOSITIONS, AND KITS FOR THE TREATMENT OF CANCER | THE GENERAL HOSPITAL CORPORATION (US) | 2014-11-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140335050-A1 | METHODS, COMPOSITIONS, AND KITS FOR THE TREATMENT OF CANCER | IL2RA, CD74, IL2 | TRPV6 3741/4885SLC18A3 2366/4885SIGMAR1 409/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.